Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of oral CC-99282 alone and with anti-lymphoma agents in relapsed or refractory non-Hodgkin lymphoma
CTR20232488Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golcadomide, rituximab in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), sponsored by Celgene Corporation. Started Dec 2023; status: active.
02
Drugs
golcadomiderituximab
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20232488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232488.